相关实验视频
Updated: May 11, 2025

12:03
In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis
Published on: December 9, 2016
12.3K
铁氨酸激酶抑制剂在尤文肉瘤:一个系统的审查
Ahmad Assi1, Mohamad Farhat2, Rami Mohanna2
1Hematology-Oncology Department, Hotel Dieu de France, Beirut, Lebanon. a.m.assi@hotmail.com.
BMC cancer
|April 18, 2025
概括
尤文肉瘤 (ES) 是一种罕见的骨癌. 用抑制剂向过度表达的氨酸激酶受体 (RTKs) 显示出治疗侵略性ES的前景,特别是那些涉及IGF1R.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 尤文肉瘤 (ES) 是一种高度侵袭的儿科骨癌.
- 氨酸激酶受体 (RTK) 的过度表达在ES中很常见,并驱动其恶性表型.
- 像IGF1R和VEGFR这样的特定RTK与更具侵略性的疾病和更差的结果有关.
研究的目的:
- 审查RTKs在尤文肉瘤中的作用.
- 评估氨酸激酶抑制剂 (TKI) 在治疗ES中的潜力.
- 突出预测生物标志物和新治疗策略的需要.
主要方法:
- 关于ES中RTK表达的研究的文献综述.
- 对复发性ES中TKI疗效的临床数据的分析.
- 检查IGF1R聚焦疗法和组合疗法研究.
主要成果:
- 包括IGF1R和VEGFR在内的RTKs的过度表达与ES的攻击性有关.
- 像阿帕提尼布,安洛提尼布和卡博桑提尼布这样的TKIs在晚期ES中表现出临床活性.
- IGF1R 抑制剂和组合疗法需要进一步研究.
结论:
- 针对RTK提供了一个有前途的治疗途径,用于Ewing的肉瘤.
- 预测生物标志物的开发对于优化TKI治疗至关重要.
- 未来的研究应该集中在IGF1R抑制剂,组合疗法和生活质量评估上.
相关概念视频
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Cancer Therapies
7.4K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.4K
Inhibition of Cdk Activity
4.6K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K

